![](/img/cover-not-exists.png)
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study
Weide, Rudolf, Pandorf, Annette, Heymanns, Jochen, Köppler, HubertVolume:
45
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428190400004521
Date:
January, 2004
File:
PDF, 134 KB
english, 2004